article thumbnail

In FDA adcomm, Lexicon gets another thumbs down for type 1 diabetes hopeful Zynquista

Fierce Pharma

Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating r | Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) (..)

article thumbnail

Changing the PAP Model

Pharmaceutical Commerce

News News Pharma Pulse Academy Publications Partner Perspectives Webcasts Resources Conferences Conference Coverage Conference Listing Events Videos Videos Peer Exchange Podcasts Editorial Podcasts Sponsored Podcasts Subscribe Choose Specialty Brand & Product Security Brand & Product Security Brand & Product Security Brand & Product (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bolstering Health Technology Assessment With the Help of AI

Pharmaceutical Commerce

News News Pharma Pulse Academy Publications Partner Perspectives Webcasts Resources Conferences Conference Coverage Conference Listing Events Videos Videos Peer Exchange Podcasts Editorial Podcasts Sponsored Podcasts Subscribe Choose Specialty Brand & Product Security Brand & Product Security Brand & Product Security Brand & Product (..)

article thumbnail

A rapid microbiological method case study for advanced therapy medicinal products

European Pharmaceutical Review

ATP-bioluminescence is no exception: all cells produce ATP as an energy transport molecule, whether they are microbial in nature or contained within the cell therapy itself. ATP can even be a residual molecule from the biological sources used for medicine production.

article thumbnail

Making the Case for Case Management for Cell and Gene Therapies

As demand for advanced therapies increases, so does the need for more specialized supply chain support, as these products have strict transportation and handling requirements.

article thumbnail

Tisento’s MELAS treatment receives fast track status from FDA

Pharmaceutical Technology

Give your business an edge with our leading industry insights.

FDA 52
article thumbnail

DSCSA Compliance: The Time is Now

Pharmaceutical Commerce

News News Pharma Pulse Academy Publications Partner Perspectives Webcasts Resources Conferences Conference Coverage Conference Listing Events Videos Videos Peer Exchange Podcasts Editorial Podcasts Sponsored Podcasts Subscribe Choose Specialty Brand & Product Security Brand & Product Security Brand & Product Security Brand & Product (..)